PAT204

PAT204 is an investigational anticancer peptide candidate being developed by ProAbTech. It is designed using the company's proprietary Albubody™ platform, which focuses on creating next-generation bioconjugates with extended half-lives and improved tumor penetration. The Albubody™ technology typically involves the fusion or conjugation of therapeutic proteins or peptides to albumin-binding antibody fragments (scFv) to enhance their pharmacokinetic profile. PAT204 is currently in the early research and development (R&D) stage, with its specific biological target and primary cancer indications still under evaluation (TBD). The drug is part of a broader pipeline of long-acting biologics developed by ProAbTech, which includes treatments for rare metabolic diseases and various cancers.